Skip to main content

Table 2 Patient demographics and baseline characteristics.

From: Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients

  Non-EBRT
(n= 49)
EBRT
(n= 35)
P-value
Sex, n (%)    0.308
   Male 32 (65.3%) 19 (54.3%)  
   Female 17 (34.7%) 16 (45.7%)  
Age, n (%)    0.631
   ≤60 years old 25(51.0%) 16 (45.7%)  
   >60 years old 24(49.0%) 19 (64.3%)  
Clinical symptoms, n (%)    0.386
   Asymptomatic 9(18.4%) 4 (11.4%)  
   Symptomatic 40(81.6%) 31 (88.6%)  
Diameter, mean ± SE (cm) 8.6 ± 3.4 7.7 ±3.2 0.238
   ≤5, n (%) 6(12.2%) 7 (20.0%) 0.280
   5-10, n (%) 21 (44.9%) 18 (51.4%)  
   ≥10, n (%) 22 (44.9%) 10 (28.6%)  
Intrahepatic lesions, n (%)    0.898
   Solitary 37(75.5%) 26 (74.3%)  
   Multiple nodules 12 (24.5%) 9 (25.7%)  
Tumor Types, n (%)    0.722
   Peripheral ICC 34 (69.4%) 23 (65.7%)  
   Central ICC 15 (30.6%) 12 (34.3%)  
Synchronous LN metastases, n (%)    0.064
   No 18 (36.7%) 20 (57.1%)  
   Yes 31 (63.3%) 15 (42.9%)  
CA19-9, U/mL    0.676
   ≤37, n (%) 9 (18.4%) 4 (11.4%)  
   37-600, n (%) 15 (30.6%) 11 (31.4%)  
   ≥600, n (%) 25 (51.0%) 20 (57.1%)  
TACE, n (%)    0.118
   Yes 13(26.5%) 15(42.9%)  
   No 36(73.5%) 20(57.1%)  
TNM stage, n (%)    0.175
   I   1(2.9%)  
   II 6(12.2%) 8(22.9%)  
   III 10(20.4%), 9(25.7%)  
   IVA 29(59.2%) 12(34.3%)  
   IVB 4(8.2%) 5(14.3%)  
  1. EBRT, external beam radiotherapy; TACE, transcatheter arterial chemoembolization; SE, standard error; ICC, intrahepatic cholangiocarcinoma; LN, lymph node.